Neuronal glucose metabolism and schizophrenia: therapeutic prospects? (Q37610162)

21 August 2017

Neuronal glucose metabolism and schizophrenia: therapeutic prospects? (English)

1 reference

21 August 2017

0 references

0 references

Donard S Dwyer

1

1 reference

21 August 2017

Xiao-Hong Lu

series ordinal

2

1 reference

21 August 2017

Arthur M Freeman Iii

series ordinal

3

1 reference

21 August 2017

1 January 2003

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

21 August 2017

1 reference

21 August 2017

3

1 reference

21 August 2017

29-40

1 reference

21 August 2017

1

1 reference

Trends in the prescribing of psychotropic medications to preschoolers

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Implications of normal brain development for the pathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

The reduced neuropil hypothesis: a circuit based model of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Schizophrenia as a disorder of developmentally reduced synaptic connectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Schizophrenia as a disorder of neurodevelopment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Clozapine for the treatment of adolescents with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Suicide among female adolescents: characteristics and comparison with males in the age group 13 to 22 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Antipsychotic drug treatment in the prodromal phase of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Another view of therapy for cognition in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Olanzapine for autistic disorder with hyperactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Open-label study of olanzapine in children with pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Olanzapine induces remarkable weight gain in adolescent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Quetiapine for refractory schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Experience with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Ziprasidone: profile on safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Glucose transport and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Neuroprotective effects of an adenoviral vector expressing the glucose transporter: a detailed description of the mediating cellular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Enhancing cognitive function across the life span

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Effects of glucose on memory processes in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Neuropsychological change in young people at high risk for schizophrenia: results from the first two neuropsychological assessments of the Edinburgh High Risk Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Neuronal nicotinic receptors in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

The role of thiamine in nervous tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Synthesis of thiamine triphosphate in rat brain in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

Acetazolamide and thiamine: an ancillary therapy for chronic mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.3.1.29

21 January 2018

Identifiers

DOI

10.1586/14737175.3.1.29

1 reference

release_pxfcj5xskvgd7ovqqre6bj7zmu

21 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pxfcj5xskvgd7ovqqre6bj7zmu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference